IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
First-Line Therapy for Chronic Graft-versus-Host Disease that Includes Low-Dose Methotrexate Is Associated with a High Response Rate
Wang, Yu; Xu, Lan-ping; Liu, Dai-hong; Chen, Huan; Chen, Yu-hong; Han, Wei; Liu, Kai-yan; Huang, Xiao-jun
关键词Hematopoietic Stem Cell Transplantation Allogeneic Methotrexate Chronic Graft-versus-host Disease
刊名BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
2009-04-01
DOI10.1016/j.bbmt.2008.12.493
15期:4页:505-511
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology ; Immunology ; Transplantation
研究领域[WOS]Hematology ; Immunology ; Transplantation
关键词[WOS]STEM-CELL TRANSPLANTATION ; MARROW TRANSPLANTATION ; SALVAGE THERAPY ; CYCLOSPORINE ; PROPHYLAXIS ; THALIDOMIDE ; MECHANISMS ; TACROLIMUS
英文摘要

We report the results of low-dose methotrexate (MTX) as first-line therapy mostly in combination with other immunosuppressive agents in patients with chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Between November 2001 and March 2008,86 patients with cGVHD after allo-HSCT received low-dose MTX therapy until a complete or partial response (CR, PR) was achieved, or until treatment failure or intolerable side effects were found. The median time from HSCT to the start of MTX was 154 (range: 80-993) days. The median number of MTX administrations was 4 (range: 2-18). The overall response rate among all enrolled patients was 83% (71 of 86 patients). The response rate for GVHD involving various organs was 90% (45 of 50) in the skin, 75% (39 of 52) in the liver, 42% (5 of 12) in the mouth, 3 of 7 in the eye, and 2 of 2 in the gut. In addition, MTX treatment allowed for a significant reduction in the prednisone dosage (median 90%) from 20 (2.5-100) mg at the start of MTX administration to 5 (0-30) mg 1 month after MTX was last used. Multivariate analysis showed that the only significant factor related to higher CR rate was sole organ involvement (P = .007). Grade 3 toxicities occurred in only 3 patients presenting cytopenias or oral mucositis. From this analysis, MTX appears to be a well-toletated, effective, and inexpensive agent when used as a first-line treatment in combination with other immunosuppressive agents for cGVHD, especially for skin or sole organ involvement without concomitant thrombocytopenia.

语种英语
WOS记录号WOS:000264616000014
Citation statistics
Cited Times:11[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51170
Collection北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
Recommended Citation
GB/T 7714
Wang, Yu,Xu, Lan-ping,Liu, Dai-hong,et al. First-Line Therapy for Chronic Graft-versus-Host Disease that Includes Low-Dose Methotrexate Is Associated with a High Response Rate[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2009,15(4):505-511.
APA Wang, Yu.,Xu, Lan-ping.,Liu, Dai-hong.,Chen, Huan.,Chen, Yu-hong.,...&Huang, Xiao-jun.(2009).First-Line Therapy for Chronic Graft-versus-Host Disease that Includes Low-Dose Methotrexate Is Associated with a High Response Rate.BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,15(4),505-511.
MLA Wang, Yu,et al."First-Line Therapy for Chronic Graft-versus-Host Disease that Includes Low-Dose Methotrexate Is Associated with a High Response Rate".BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 15.4(2009):505-511.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Wang, Yu]'s Articles
[Xu, Lan-ping]'s Articles
[Liu, Dai-hong]'s Articles
百度学术
百度学术Similar articles in
[Wang, Yu]'s Articles
[Xu, Lan-ping]'s Articles
[Liu, Dai-hong]'s Articles
必应学术
必应学术Similar articles in
[Wang, Yu]'s Articles
[Xu, Lan-ping]'s Articles
[Liu, Dai-hong]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.